HC Wainwright Reaffirms “Buy” Rating for Enanta Pharmaceuticals (NASDAQ:ENTA)

Enanta Pharmaceuticals (NASDAQ:ENTA)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a report released on Tuesday,Benzinga reports. They presently have a $18.00 target price on the biotechnology company’s stock. HC Wainwright’s price objective would indicate a potential upside of 207.17% from the company’s previous close.

Several other equities research analysts also recently weighed in on the stock. JMP Securities reiterated a “market outperform” rating and set a $21.00 target price (down previously from $22.00) on shares of Enanta Pharmaceuticals in a research note on Tuesday, November 26th. Robert W. Baird decreased their price objective on Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating for the company in a research report on Tuesday, November 26th. Two analysts have rated the stock with a sell rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $17.25.

Enanta Pharmaceuticals Trading Up 4.8 %

Shares of NASDAQ ENTA opened at $5.86 on Tuesday. The stock has a market cap of $124.99 million, a P/E ratio of -1.07 and a beta of 0.54. Enanta Pharmaceuticals has a twelve month low of $4.71 and a twelve month high of $17.80. The stock has a 50 day moving average of $5.80 and a two-hundred day moving average of $9.54.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its earnings results on Monday, February 10th. The biotechnology company reported ($1.05) EPS for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative net margin of 171.57% and a negative return on equity of 73.02%. As a group, research analysts predict that Enanta Pharmaceuticals will post -5.05 earnings per share for the current year.

Insider Transactions at Enanta Pharmaceuticals

In related news, CEO Jay R. Luly sold 5,142 shares of Enanta Pharmaceuticals stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $8.06, for a total value of $41,444.52. Following the sale, the chief executive officer now directly owns 801,638 shares in the company, valued at $6,461,202.28. The trade was a 0.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 13.89% of the company’s stock.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. Krensavage Asset Management LLC grew its stake in shares of Enanta Pharmaceuticals by 19.7% during the 3rd quarter. Krensavage Asset Management LLC now owns 1,498,074 shares of the biotechnology company’s stock worth $15,520,000 after purchasing an additional 246,736 shares during the period. Erste Asset Management GmbH purchased a new position in Enanta Pharmaceuticals in the third quarter valued at about $1,243,000. Point72 Asset Management L.P. purchased a new position in Enanta Pharmaceuticals in the third quarter valued at about $903,000. JPMorgan Chase & Co. lifted its position in shares of Enanta Pharmaceuticals by 53.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 243,628 shares of the biotechnology company’s stock valued at $2,524,000 after acquiring an additional 85,082 shares during the period. Finally, Trexquant Investment LP boosted its stake in shares of Enanta Pharmaceuticals by 97.3% during the 4th quarter. Trexquant Investment LP now owns 135,954 shares of the biotechnology company’s stock worth $782,000 after acquiring an additional 67,040 shares in the last quarter. Institutional investors and hedge funds own 94.99% of the company’s stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.